Virtual Reality Exercise Intradialysis: Tolerance and Dialysis Dose Effects During the Last vs. First Part of the Hemodialysis Session

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The main objective of this investigation is to assess if an intradialysis virtual reality exercise program during the last two hours of the hemodialysis session results in greater hemodynamic stability than exercise performed during the first two hours of the hemodialysis session. The secondary aims are to assess the impact of intradialysis virtual reality exercise during the last two hours of the hemodialysis session on dialysis efficacy, postdialysis molecules rebound, adherence to exercise, functional capacity, physical activity level, health-related quality of life, cognitive function, morbidity, frailty and dependency. We will also analyze the reliability of muscle strength assessment of lower limb muscles with a handheld dynamometer during hemodialysis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• At least 3 months in hemodialysis treatment

• Clinically stable

Locations
Other Locations
Spain
Hospital de Manises
RECRUITING
Manises
Contact Information
Primary
Eva Segura-Ortí, PhD
eva.segura@gmail.com
00 34 671580094
Backup
Alicia García-Testal, PhD
Agtestal@gmail.com
00 34 637519626
Time Frame
Start Date: 2019-09-02
Estimated Completion Date: 2024-08-30
Participants
Target number of participants: 50
Treatments
Active_comparator: Conventional exercise time
During 12 months subjects will exercise during the first two hours of the hemodialysis session. A virtual reality exercise program will be implemented
Experimental: Experimental group
During 12 months subjects will exercise during the last two hours of the hemodialysis session. A virtual reality exercise program will be implemented
Related Therapeutic Areas
Sponsors
Collaborators: Hospital de Manises, Universitat Politècnica de Valéncia
Leads: Cardenal Herrera University

This content was sourced from clinicaltrials.gov